Epidermal growth factor receptor in non-small cell lung cancer

Following the identification of a group of patients in the initial tyrosine kinase inhibitor (TKI) trials for lung cancer, there has been detailed focus on which patients may benefit from inhibitor therapy. This article reviews the background, genetics and prevalence of epidermal growth factor mutations in nonsmall cell lung cancer (NSCLC). Additionally, the prevalence in unselected patients is compared against various other reviews.